Unlocking Cardiac AI’s Trillion-Dollar Prevention Market

The way we practice cardiology is changing, and it’s not a slow drift. We’re moving from a defensive, reactive posture to an offensive game plan built on AI-powered networks. These systems are starting to give us real-time alerts about cardiac risks, which could completely change patient outcomes and how diseases progress. For any practicing cardiologist, getting a handle on what these platforms can do and what they mean for the clinic isn’t just a good idea, it’s part of staying current in our field.

The AI-Powered Shift in Cardiovascular Prevention: A Systematic Review

AI and connected care are reshaping heart disease prevention right now. This review is a framework for clinicians to make sense of the new tools out there. We’re focused on companies that are actually in clinics and have the data to back up what they’re doing, looking at them through the same evidence-based lens we’d use for a new clinical practice guideline, that means FDA clearance and peer-reviewed results are key. The real question is, what does this mean for my day-to-day practice? To get at that, we’re looking at three major players and what they’re doing in cardiac AI monitoring diagnostics and AI heart health platforms: Viz.ai, Paige AI, and Tempus AI.

Viz.ai: Orchestrating Acute Cardiovascular Care Pathways

Viz.ai has made a name for itself in AI-based care coordination, first getting traction with its stroke detection tools. Now, they’re pushing into cardiovascular modules, which is a big move toward a unified system for acute cardiac events. The Viz.ai platform uses deep learning to scan medical images like CTs, flagging critical findings that point to a pulmonary embolism or aortic dissection. Their track record is solid. For example, clinical trials for their stroke modules show they drastically cut down treatment times, with one study showing a real drop in door-to-needle times for thrombectomy patients using their triage and communication platform Viz.ai stroke clinical trial results. Although we’re still waiting for a full set of published, independent trial results just for their cardiac tools, Viz.ai got a big win in August 2023 when the FDA granted De Novo approval for its Viz HCM (Hypertrophic Cardiomyopathy) module, which actually created a whole new regulatory class for this kind of software. Viz HCM is the only FDA-cleared AI that helps clinicians spot signs of HCM on a standard 12-lead ECG. They’ve also secured 510(k) clearances for modules like Viz AAA (abdominal aortic aneurysm) and Viz ANEURYSM (cerebral aneurysms), showing they’re serious about regulatory validation. Their success in neurology and these specific cardiac clearances give us a good reason to trust their algorithms and their ability to fit into a hospital’s workflow. For cardiologists, the payoff is catching critical problems that show up in the ED much earlier, letting us get a consult and intervene faster. That has a direct effect on patient morbidity and mortality by cutting the time and complexity from diagnosis to treatment.

Paige AI: Expanding Diagnostic Frontiers from Oncology to Systemic Pathology

Paige AI is best known for its work in computational pathology for cancer, but the AI engine they’ve built and its diagnostic accuracy should have the cardiovascular world paying attention. The core of what Paige AI does is analyze huge numbers of digital pathology slides with incredible accuracy, picking up on subtle patterns that signal disease. The proof is in their oncology work, where their diagnostic sensitivity often beats human pathologists at certain tasks Paige AI oncology diagnostic sensitivity study. The company has hit some major regulatory goals, getting the first ever FDA authorization for an AI in pathology with Paige Prostate Detect back in 2021 and a Breakthrough Device designation in April 2026 for Paige PanCancer Detect, which is designed to help pathologists find cancer across many different tissue types. It’s only a matter of time before this kind of powerful AI gets pointed at systemic diseases, including cardiovascular pathology. You can easily see how AI analysis of an endomyocardial biopsy for myocarditis or amyloidosis could give us a more precise diagnosis much sooner than we get now. There aren’t many direct, peer-reviewed studies on Paige AI for cardiac pathology just yet, but given their proven skill in reading complex images, they are set up to be a major force here. For us, this means tissue-based diagnostics for heart disease could get a huge boost from AI, leading to more definitive diagnoses and truly personalized treatments instead of relying on more subjective interpretations.

Tempus AI: Genomic Insights and Precision Cardiovascular Risk Stratification

Tempus AI comes at cardiovascular prevention from a different, but just as powerful, direction using genomic sequencing and precision medicine algorithms. Their platform takes massive genomic datasets, combines them with clinical data, and then uses machine learning to find people at high risk for a whole range of cardiovascular problems. The data from Tempus AI’s integration of genomics and cardiology is pretty convincing, showing what’s possible with personalized risk models. They’re doing fascinating work with ECG-based machine learning that can spot subtle electrical signs that predict future cardiac events, even in people who look perfectly healthy. Tempus has already collected multiple FDA 510(k) clearances for its cardiac AI tools, like Tempus ECG-AF for flagging patients at higher risk for atrial fibrillation and Tempus ECG-PH for finding signs of pulmonary hypertension on a standard ECG. They didn’t stop there. In September 2025, Tempus got another 510(k) for an updated Tempus Pixel, their AI-based cardiac imaging platform. And in September 2026, they landed up to $9.5 million in ARPA-H ADVOCATE funding to build an autonomous AI agent for heart failure care. Pulling these ECG and imaging insights together with a full genomic profile gives us a much more detailed and predictive picture of a person’s risk than something like a Framingham score. This “AI heart health platform” approach could change everything about primary and secondary prevention. For cardiologists, Tempus AI lets us get away from population-based risk scores and create truly individual prevention plans. When you can combine a genetic predisposition for arrhythmia or hyperlipidemia with an AI that flags a change on a routine test, you can make targeted interventions years earlier and potentially stop the disease before it even starts.

Actionable Insights for Clinical Practice

AI in cardiology isn’t some far-off concept. It’s here now. The big task for cardiologists is figuring out how to fold these new AI alerts and insights into our existing decision-making process. 1. Viz.ai’s acute care orchestration: We need to be ready for AI-driven alerts that speed up referrals for things like hypertrophic cardiomyopathy or aortic aneurysms. Our teams need to know the communication protocols and data feeds from these platforms so we can smoothly integrate them into our ER and inpatient workflows. That means having clear departmental guidelines for how we’re expected to react to an urgent AI-generated notification.

1. Paige AI’s diagnostic augmentation: Even though it’s still early for direct cardiac pathology, it’s clear that AI is going to make tissue-based diagnostics faster and more precise. As this tech gets better, we should think about how AI-assisted pathology reports could sharpen our diagnoses for complex heart conditions that depend on a tissue sample for confirmation.
2. Tempus AI’s precision prevention: The role of genomics and AI-driven risk models in preventive cardiology is only going to grow. We have to understand what a genetic predisposition found by a platform like Tempus AI means for guiding a patient’s lifestyle, drug therapy, and screening schedule, especially with their FDA-cleared ECG tools for afib and pulmonary hypertension. This is going to change how we talk to patients about their personal risk and prevention plans. Learning this stuff isn’t optional. It’s a professional responsibility, and staying on top of it is the only way we’ll be able to use AI to its full potential for our patients.
   

   Methodology Note: Guiding Safe Clinical Adoption

In our analysis, we’re sticking to FDA-cleared algorithms and studies that have been through peer review. This is the only way to sort the real, clinically useful solutions from the speculative tech promises. The FDA’s 510(k) clearance process basically tells you that a device is safe and effective because it’s very similar to something already on the market (it’s not a statement of superiority). For brand-new AI functions, a De Novo classification or a Breakthrough Device Designation means the tech has been through an even more intense evaluation. Looking at these regulatory approvals, along with independent clinical studies, is the only responsible way to bring AI into cardiology. As this all moves forward, sticking to Good Machine Learning Practice (GMLP) principles will be absolutely necessary to make sure these powerful tools are reliable and used ethically.